Tuesday, September 30, 2014 12:01:02 PM
Your post:
Personally, I have been trading NNVC with very limited amounts and taking fast gains. Currently, I have no position, as I have found better investment opportunities elsewhere. But, if I had cash available, I would have taken a position at $3 this morning. At minimum, I would expect an abbreviated dead cat bounce.
For the patient investor, I think current levels are fairly secure; however, I think there may be one more leg down to the $2.71 area.
I agree with your assessment, there is probably more than rational pessimism at play. NNVC approaching the fear level, and that usually means BUY. I also think positive news will jettison the stock very quickly. There is a fair possibility for this. Seem that Dr. Seymour is being very guarded and cautious in his public statements.
Bottom line, I think NNVC is at or near bottom. Could be another 10% to the downside. The upside is much, much more. For the prudent trader, it would be wise to wait for the appropriate buy signals. Would look for consolidation, then a high volume green day (40% above normal).
NNVC continues to be volatile and risky. But, much less risky than when it was trading at $4.50,a few months ago.
I still keep a close eye on NNVC, and believe it may be a rainmaker some day. Over the past several years, I have made a significant amount trading NNVC. I had a pretty sizeable position for over one year. Timing, timing, timing!!!
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM